Skip to main content

Table 4 Number of Patients with Data Available and Number Excluded due to Missing Dataa After METTb

From: Effects of dexrazoxane on doxorubicin-related cardiotoxicity and second malignant neoplasms in children with osteosarcoma: a report from the Children’s Oncology Group

Variable LV Fractional Shortening Z-scores LV End-Diastolic Dimension Z-scores LV End-Diastolic Posterior Wall Thickness Z-scores LV Thickness to Dimension Ratio Z-scores End-Diastolic Septal Thickness Z-scores LV Mass Z-scores NT-proBNP
Overall n = 229 n = 224 n = 221 n = 228 n = 212 n = 214 n = 156
(n = 148) (n = 146) (n = 143) (n = 146) (n = 142) (n = 140) (n = 97)
AOST0121 n = 90 n = 85 n = 83 n = 89 n = 83 n = 82 n = 42
(n = 82) (n = 80) (n = 78) (n = 80) (n = 78) (n = 77) (n = 27)
P9754 n = 139 n = 139 n = 138 n = 139 n = 129 n = 132 n = 114
(n = 66) (n = 66) (n = 65) (n = 66) (n = 64) (n = 63) (n = 70)
  1. aNumber of patients with missing data in parenthesis for each variable
  2. bMETT minimum expected treatment time